AnaptysBio, Inc.

126 articles with AnaptysBio, Inc.

• 

  AnaptysBio CEO Exits After Decade in the Role

  3/22/2022

  ​​​​​​​In the interim, Daniel Faga will take the helm as president and CEO after Hamza Suria let go of his executive functions. 
• 

  Clinical Catch-Up: New SMA and Alzheimer's Data

  3/21/2022

  It was a busy week for clinical trial announcements. Here's a look.

• AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

  3/21/2022

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Daniel Faga as interim president and chief executive officer (CEO), effective immediately.

• 

  Second March Readout Not the Charm for AnaptysBio as Imsidolimab Misses Again

  3/15/2022

  AnaptysBio announced that its drug candidate imsidolimab did not demonstrate efficacy in Phase II clinical trials in the treatment of moderate-to-severe acne.

• AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne

  3/14/2022

  AnaptysBio, Inc. (Nasdaq: ANAB), today announced that top-line data from its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne, also known as the ACORN trial, did not demonstrate efficacy over placebo on primary or secondary endpoints. 

• AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update

  3/7/2022

  AnaptysBio, Inc. today reported operating results for the fourth quarter and year ended December 31, 2021 and provided pipeline updates.

• AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/5/2022

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio as part of the 40th Annual J.P. Morgan Healthcare Conference.

• AnaptysBio Announces Appointment of Daniel Faga to Board of Directors

  11/29/2021

  AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, announced the appointment of Mr. Daniel Faga to the company’s Board of Directors.

• AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference

  11/16/2021

  AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the 2021 Jefferies London Healthcare Conference.

• AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data

  11/15/2021

  AnaptysBio, Inc. (Nasdaq: ANAB), today announced positive top-line data from a randomized placebo-controlled healthy volunteer single and multiple ascending dose Phase 1 trial of rosnilimab, its investigational wholly-owned anti-PD-1 agonist therapeutic antibody, previously known as ANB030.

• AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates

  11/4/2021

  AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, reported operating results for the third quarter ended September 30, 2021 and provided pipeline updates.

• AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis

  10/2/2021

  AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, announced that week 16 data from the GPP GALLOP Phase 2 trial of imsidolimab, its investigational anti-interleukin-36 receptor therapeutic antibody, was presented at the 2021 European Academy of Dermatology and Venereology Congress.

• FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

  8/17/2021

  AnaptysBio, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved a second indication for GSK’s JEMPERLI (dostarlimab-gxly)

• AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates

  8/9/2021

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the second quarter ended June 30, 2021 and provided pipeline updates.

• AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

  5/27/2021

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference

• AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

  5/4/2021

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the first quarter ended March 31, 2021 and provided pipeline updates.

• European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

  4/23/2021

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the European Commission has granted conditional marketing authorization for JEMPERLI (dostarlimab)

• FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

  4/22/2021

  PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK) First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to Obtain FDA Approval $20MM Milestone Payment Earned by AnaptysBio Upon FDA Approval; Additional $45MM and $165MM Milestones Due Upon Dostarlimab Regulatory and Commercial Milestones, Respectively AnaptysBio Due to Receive 8% to 25% Royalty on Global Net Sales

• AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

  4/12/2021

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Oleg Nodelman to the company’s Board of Directors.   

• 

  Antibody Drug Fails to Beat Placebo in Trial for Rare Inflammatory Skin Condition

  3/8/2021

  AnaptysBio started the week with some disappointing news for its lead antibody drug imsidolimab.